Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
4 března, 2021 6:13 pm Leave your thoughtsAuthor(s): Ruediger Hehlmann, Michael Lauseker, Susanne Saussele, et al. Abstract: S424 Session topic: 8. Chronic myeloid leukemia –...
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
4 března, 2021 6:11 pm Leave your thoughtsAuthor(s): Timothy Hughes, Carla Boquimpani, Naoto Takahashi, et al. Abstract: P257 Session topic: 8. Chronic myeloid leukemia –...
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
4 března, 2021 6:09 pm Leave your thoughtsAuthor(s): Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al. Abstract: P605 Session topic: 8. Chronic myeloid leukemia –...
Aktuality z EHA 2017 zaměřené na chronickou myeloidní leukemii
4 března, 2021 6:07 pm Leave your thoughtsChronická myeloidní leukemie (CML) je klonální myeloproliferativní onemocnění, které představuje 15–25 % nově diagnostikovaných leukemií dospělého věku. Je příkladem onemocnění, u kterého...
POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP
4 března, 2021 6:05 pm Leave your thoughtsAuthor(s): Ludek Pour, Lucie Brozova, Ivan Spicka, et al. Abstract: S 1290 Session topic: 14. Myeloma and other...
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
4 března, 2021 6:03 pm Leave your thoughtsAuthor(s): Charlotte Pawlyn, Faith Davies, David Cairns, et al. Abstract: S 781 Session topic: 14. Myeloma and other...
MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL
4 března, 2021 5:54 pm Leave your thoughtsAuthor(s): Stefania Oliva, Davine Hofste op Bruinink, Lucie Říhová, et al. Abstract: S 102 Session topic: 13. Myeloma...
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
4 března, 2021 5:51 pm Leave your thoughtsAuthor(s): Jesus San-Miguel, Katja Weisel, Gordon Cook, et al. Abstract: S 101 Session topic: 14. Myeloma and other...
MNOHOPOČETNÝ MYELÓM
4 března, 2021 5:49 pm Leave your thoughtsNa kongrese EHA 2017 bol mnohopočetnému myelómu (MM) venovaný značný priestor v rámci edukačného a satelitných sympózií, vedeckej pracovnej skupiny a taktiež v posterovej sekcii....
QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
4 března, 2021 5:37 pm Leave your thoughtsAuthor(s): Nigel Russell, Martin S. Tallman, Stuart Goldberg Abstract: ABSSUB-4757 Session topic: 4. Acute myeloid leukemia – Clinical...